Skip to main content
SpringerLink
Log in

Ticagrelor: a guide to its use in the management of acute coronary syndromes

  • Clinical Questions & Answers on Drugs
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Ticagrelor, an oral antiplatelet agent, is indicated for the prevention of atherothrombotic events in adults with acute coronary syndromes. In this population, ticagrelor was more effective than clopidogrel in preventing ischaemic events over 12 months, providing a significantly lower risk of the primary composite endpoint of myocardial infarction, stroke or death from vascular causes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1

Similar content being viewed by others

References

  1. Deeks ED. Ticagrelor: a review of its use in the management of acute coronary syndromes. Drugs 2011; 71(7): 909–33

    Article  PubMed  CAS  Google Scholar 

  2. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007 Jul; 28(13): 1598–660

    Article  PubMed  CAS  Google Scholar 

  3. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. The Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008 Dec; 29(23): 2909–45

    Article  PubMed  Google Scholar 

  4. Brilique 90 mg film-coated tablets: summary of product characteristics. London: European Medicines Agency, 2011 Jan 7

  5. Brillinta™ (ticagrelor) tablets, for oral use: US prescribing information. Wilmington (DE): AstraZeneca LP, 2011 Jul

  6. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009 Sep 10; 361(11): 1045–57

    Article  PubMed  CAS  Google Scholar 

  7. James S, Åkerblom A, Cannon CP, et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 2009 Apr; 157(4): 599–605

    Article  PubMed  CAS  Google Scholar 

  8. James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the PLATelet inhibition and patient Outcomes (PLATO) trial. Circulation 2010 Sep 14; 122(11): 1056–67

    Article  PubMed  Google Scholar 

  9. James S, Angiolillo DJ, Cornel JH, et al. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010 Dec; 31(24): 3006–16

    Article  PubMed  CAS  Google Scholar 

  10. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010 Oct 16; 376(9749): 1320–8

    Article  PubMed  CAS  Google Scholar 

  11. Cannon CP, Harrington RA, James S, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 2010 Jan 23; 375(9711): 283–93

    Article  PubMed  CAS  Google Scholar 

  12. Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a PLATelet inhibition and patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010 Nov 23; 122(21): 2131–41

    Article  PubMed  Google Scholar 

  13. Storey RF, Becker RC, Cannon CP, et al. Ticagrelor does not affect pulmonary function tests compared to clopidogrel in acute coronary syndromes: results of the PLATO pulmonary substudy [abstract no. 1100-276]. J Am Coll Cardiol 2010 Mar 9; 55: A108: E1007

    Article  Google Scholar 

  14. Varenhorst C, Alstrom U, Scirica BM, et al. Cardiac events, infections and bleed contribute to higher vascular and non-vascular mortality with clopidogrel compared to ticagrelor treatment in patients undergoing coronary artery bypass grafting [abstract no. P2428]. Eur Heart J 2011; 32Suppl. 1: 414

    Google Scholar 

  15. Final appraisal determination: ticagrelor for the treatment of acute coronary syndromes. London: National Institute for Health and Clinical Excellence, 2011 Sep

Download references

Author information

Authors and Affiliations

  1. a Wolters Kluwer Business, Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Lesley J. Scott & Emma D. Deeks

Authors
  1. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emma D. Deeks
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lesley J. Scott.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scott, L.J., Deeks, E.D. Ticagrelor: a guide to its use in the management of acute coronary syndromes. Drugs Ther Perspect 28, 1–5 (2012). https://doi.org/10.2165/11606170-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11606170-000000000-00000

Keywords

Search

Navigation